Related Experiment Video

Updated: Feb 16, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

Current systemic therapies for metastatic renal cell carcinoma in older adults: A comprehensive review

Manuel Caitano Maia1, Jacob Adashek2, Paulo Bergerot1

  • 1Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.

Journal of Geriatric Oncology
|December 19, 2017
PubMed

Insights

Older adults with metastatic renal cell carcinoma (mRCC) need tailored treatment. This review covers age-related changes and new drug data to guide optimal care for this understudied population.

Area of Science:

  • Geriatric oncology
  • Pharmacology
  • Renal cell carcinoma research

Background:

  • Aging affects drug metabolism, impacting treatment efficacy and safety in older adults.
  • Metastatic renal cell carcinoma (mRCC) primarily affects older individuals, yet they are under-represented in clinical trials.
  • Older mRCC patients face unique challenges including comorbidities, polypharmacy, and frailty.

Purpose of the Study:

  • To review age-related metabolic differences relevant to drug therapy in older adults.
  • To analyze safety and efficacy data of approved agents for mRCC in the context of aging.
  • To provide guidance for managing older patients with mRCC, addressing under-treatment concerns.

Main Methods:

  • Comprehensive literature review of age-related physiological changes impacting drug disposition.
  • Systematic analysis of clinical trial data and real-world evidence for mRCC treatments in older populations.
  • Examination of geriatric assessment tools and their role in treatment selection.

Main Results:

  • Significant age-related variations in drug metabolism and pharmacokinetics exist.
  • Efficacy and safety profiles of mRCC drugs may differ in older adults compared to younger populations.
  • Geriatric assessments are crucial for identifying vulnerabilities and optimizing treatment strategies.

Conclusions:

  • Tailored treatment approaches are essential for older adults with mRCC, considering physiological changes and comorbidities.
  • Current guidelines recommend geriatric assessments to ensure appropriate systemic therapy selection.
  • Further research is needed to optimize the use of novel mRCC agents in the aging population.
Keywords:
OlderSystemicTreatmentmRCC

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
261
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
232
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
492
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K